fda statement bpc-157 not approved fda.gov The Food and Drug Administration's committee on compounded drugs broke with agency scientists and voted in favor of adding peptides to the list of substances compounding pharmacies can make. Follow the link FDA panel votes to add

FDA panel votes to add peptides to permitted list despite opposition from agency scientists The biggest regulatory moment for peptides in 2026 happens this week. On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee meets to vote on whether BPC 157, TB 500, KPV, MOTS c, DSIP Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions PMC An FDA advisory committee voted Thursday to remove compounding restrictions on four peptides despite little evidence the products are safe or effective for medical use. In a series of 8 6 votes (with BPC 157 PASSED! Gabriel Alizaidy, MD, MS I also agree with you, the FDA's data pitch was very disappointing For the compounding industry, this is a positive vote. It does not immediately make BPC 157 vs. TB 500: What Patients Should Know

SKU: 20195533689 · From southroadsurgery.com.au